410 related articles for article (PubMed ID: 11365404)
1. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
2. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
4. [AIDS; new developments. II. Treatment of HIV infection].
Borleffs JC; Esseveld F; Hoepelman IM; Boucher CA
Ned Tijdschr Geneeskd; 1997 May; 141(21):1036-43. PubMed ID: 9340560
[TBL] [Abstract][Full Text] [Related]
5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
6. Antiviral update.
PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972
[TBL] [Abstract][Full Text] [Related]
7. Rescue me.
Simmons P
Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
[TBL] [Abstract][Full Text] [Related]
8. Protease inhibitors at a glance...
Notes Undergr; 1998-1999 Winter; (No 38):suppl 1-4. PubMed ID: 11366198
[TBL] [Abstract][Full Text] [Related]
9. HIV resistance: the new enemy.
Colvin R
Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
[TBL] [Abstract][Full Text] [Related]
10. Update on nevirapine: quest for a niche.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):37-43. PubMed ID: 11364713
[TBL] [Abstract][Full Text] [Related]
11. Understanding the reverse transcriptase inhibitors in HIV.
Edmonds-Ogbuokiri J
Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
[TBL] [Abstract][Full Text] [Related]
12. Update from the 5th Conference on Retroviruses and Opportunistic Infections.
Vazquez E
Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483
[TBL] [Abstract][Full Text] [Related]
13. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
14. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
Wilkins E
J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
[No Abstract] [Full Text] [Related]
15. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
Vella S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapies.
Owen WF
Clin Podiatr Med Surg; 1998 Apr; 15(2):227-39. PubMed ID: 9576051
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment -- study results.
Treat Rev; 1996 Dec; (No 23):4-11. PubMed ID: 11364282
[TBL] [Abstract][Full Text] [Related]
19. Another take on when to start and how to succeed.
Friedland GH
AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
[No Abstract] [Full Text] [Related]
20. HIV antiviral drug guide 1998.
Whitfield L
Posit Aware; 1998; 9(1):28, 30-42. PubMed ID: 11364998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
